Cargando…
Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
This phase 1, open‐label, dose‐escalation study was conducted to determine the safety, tolerability, pharmacokinetics and preliminary efficacy of veliparib with carboplatin and weekly paclitaxel in Japanese women with newly diagnosed, advanced ovarian cancer. Patients received veliparib at 100 or 15...
Autores principales: | Nishio, Shin, Takekuma, Munetaka, Takeuchi, Satoshi, Kawano, Kouichirou, Tsuda, Naotake, Tasaki, Kazuto, Takahashi, Nobutaka, Abe, Masakazu, Tanaka, Aki, Nagasawa, Takayuki, Shoji, Tadahiro, Xiong, Hao, Nuthalapati, Silpa, Leahy, Terri, Hashiba, Hideyuki, Kiriyama, Tsukasa, Komarnitsky, Philip, Hirashima, Yasuyuki, Ushijima, Kimio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665762/ https://www.ncbi.nlm.nih.gov/pubmed/28837250 http://dx.doi.org/10.1111/cas.13381 |
Ejemplares similares
-
Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
por: Nishikawa, Tadaaki, et al.
Publicado: (2017) -
Identification of appropriate cone length to avoid positive cone margin in high grade cervical intraepithelial neoplasia
por: Kawano, Kouichiro, et al.
Publicado: (2016) -
Epithelial borderline ovarian tumor: Diagnosis and treatment strategy
por: Ushijima, Kimio, et al.
Publicado: (2015) -
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial
por: Mizuno, Mika, et al.
Publicado: (2022) -
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)